We present the case of a patient with aplastic anemia (AA) who was treated with
eltrombopag. To the best of our knowledge, this is the first report of the disappearance of …

Dear Editor, Eltrombopag is a small molecule thrombopoietin-receptor agonist approved to
treat patients with acquired severe aplastic anemia (SAA) with an insufficient response to …

To the Editor: A 74-year-old man diagnosed with chronic lymphocytic leukemia was started
on darbepoetin alfa (Aranesp) at a dose of 1.5 μg/kg subcutaneously once every 2 weeks for …

Objectives Eltrombopag, a thrombopoietin-receptor agonist, stimulates hematopoiesis in
patients with acquired aplastic anemia (AA). Cytomorphologic changes in bone marrow after …

Introduction. The use of thrombopoietin receptor agonists, especially eltrombopag, in the
treatment of aplastic anemia (AA) patients who did not respond to the previous …

A previously healthy 48-year-old female presented with a 4-month history of increased
symptomatic anemia and 2 weeks of heavy vaginal bleeding. She had no significant family …

About a quarter of patients with severe aplastic anemia remain pancytopenic despite
immunosuppressive therapy. We have previously demonstrated that eltrombopag has …

A 72-year-old woman was given a diagnosis of severe aplastic anemia, and treated with
anabolic steroid and cyclosporin A starting in October 1996. Because this treatment was …

We report a case of severe aplastic anemia (SAA) treated with granulocyte colony-
stimulating factor (G-CSF), cyclosporin A and danazole, in which myelodysplastic syndrome …

The major complication of severe aplastic anemia is clonal evolution, defined as any new
cytogenetic abnormality or progression to MDS/AML, which occurs in about 15% of SAA …